Movement disorders number of participants receiving antiparkinson medication · patients with schizophrenia
It is very uncertain whether perazine changes movement disorders number of participants receiving antiparkinson… compared with placebo (very low certainty).
1 finding from 1 review
Adverse effects – leaving the study early due to adverse effects – overall tolerability – total · patients with schizophrenia
1 finding from 1 review
Satisfaction with care ‐ not reported · patients with schizophrenia
The review found no eligible studies for this question.
1 finding from 1 review
Quality of life ‐ not reported · patients with schizophrenia
The review found no eligible studies for this question.
1 finding from 1 review
Global state change over time (no better or deterioration) · patients with schizophrenia
Perazine showed no clear difference in global state change over time (no better or deterioration) compared with other antipsychotics (low certainty).
1 finding from 1 review
Mental state · patients with schizophrenia
1 finding from 1 review
Cannabis use · patients with SCHIZOPHRENIA AND CANNABIS USE
1 finding from 1 review
Global state: relapse ‐ medium term ‐ not measured · patients with SCHIZOPHRENIA AND CANNABIS USE
The review found no eligible studies for this question.
1 finding from 1 review
General functioning ‐ no clinically important change in general functioning · patients with SCHIZOPHRENIA AND CANNABIS USE
The review found no eligible studies for this question.
1 finding from 1 review
Adverse effects: no clinically important adverse effects ‐ medium term ‐ not measured · patients with SCHIZOPHRENIA AND CANNABIS USE
The review found no eligible studies for this question.
1 finding from 1 review
Leaving the study early ‐ medium term ‐ not reported · patients with SCHIZOPHRENIA AND CANNABIS USE
The review found no eligible studies for this question.
1 finding from 1 review
Satisfaction with treatment ‐ medium term ‐ not measured · patients with SCHIZOPHRENIA AND CANNABIS USE
The review found no eligible studies for this question.
1 finding from 1 review
Behaviour: Cannabis use 3: Traces of cannabis breakdown products in urine ‐ medium term · patients with schizophrenia
CANNABIS REDUCTION: ANTIPSYCHOTIC 'A' showed no clear difference in behaviour: Cannabis use 3: Traces of cannabis breakdown products in… compared with ANTIPSYCHOTIC 'B' for (moderate certainty).
1 finding from 1 review
**Mental state: Obsessive–Compulsive Drug Use Scale (OCDUS) (short‐term, higher=bad) ‐ short term Scale from: 0 to 44. · patients with schizophrenia
1 finding from 1 review
Global state: relapse ‐ medium term ‐ not measured · patients with schizophrenia
The review found no eligible studies for this question.
1 finding from 1 review
General functioning ‐ no clinically important change in general functioning · patients with schizophrenia
The review found no eligible studies for this question.
1 finding from 1 review
Adverse effects: measured adverse events ‐ Simpson scale ‐ medium term Scale from: 0 to 40. · patients with schizophrenia
1 finding from 1 review
General mental state: Positive psychiatric symptom score PANSS5. Scale from: 7 to 49. · patients with SCHIZOPHRENIA AND CANNABIS USE
1 finding from 1 review
Leaving the study early ‐ medium term ‐ any reason · patients with schizophrenia
CANNABIS REDUCTION: ANTIPSYCHOTIC 'A' showed no clear difference in leaving the study early: any reason ‐ medium term compared with ANTIPSYCHOTIC 'B' for (moderate certainty).
1 finding from 1 review
Satisfaction with treatment ‐ medium term ‐ not measured · patients with schizophrenia
The review found no eligible studies for this question.
1 finding from 1 review